Betnovat: Uses, Dosage & Side Effects
A potent topical corticosteroid with anti-inflammatory and antipruritic properties for psoriasis, eczema, and other inflammatory skin conditions
Betnovat contains betamethasone valerate, a potent (Group III) topical corticosteroid that suppresses inflammation and relieves itching associated with a wide range of skin conditions. It is prescribed for psoriasis, eczema (atopic dermatitis), contact dermatitis, and other corticosteroid-responsive dermatoses. Available as an ointment, cream, cutaneous emulsion, and cutaneous solution, Betnovat allows clinicians to select the formulation best suited to the specific skin condition and body area. Its well-established efficacy and safety profile, supported by decades of clinical use and international guideline recommendations, make it one of the most widely used topical corticosteroids worldwide.
Quick Facts: Betnovat
Key Takeaways
- Betnovat contains betamethasone valerate, a potent (Group III) topical corticosteroid available as an ointment, cream, cutaneous emulsion, and cutaneous solution for inflammatory skin conditions including psoriasis, eczema, and contact dermatitis.
- Apply Betnovat thinly as directed by your doctor; do not use it daily for more than 4 weeks at a time. The ointment is best for dry, scaly skin, the cream for moist or weeping conditions, the emulsion for large or hairy areas, and the solution for the scalp.
- Do not use Betnovat on infected skin unless the infection is being treated at the same time, and avoid use on the face, groin, or underarms without specific medical instruction, as these areas are more vulnerable to skin thinning.
- Betnovat cream, ointment, and emulsion contain paraffin, which is flammable. Avoid smoking, open flames, and other ignition sources while treated skin or clothing is in contact with the product.
- After prolonged use, do not stop Betnovat abruptly. Taper gradually under medical guidance to prevent rebound inflammation or adrenal insufficiency, and consult your doctor if symptoms worsen or do not improve within 4 weeks.
What Is Betnovat and What Is It Used For?
Betnovat contains the active ingredient betamethasone valerate, a potent synthetic glucocorticosteroid that has been in clinical use for over five decades. Betamethasone valerate is classified as a Group III (potent) topical corticosteroid in the European four-tier classification system, which ranks topical steroids from mild (Group I) through moderately potent (Group II), potent (Group III), to very potent (Group IV). This classification is essential for clinical decision-making, as it helps healthcare providers select the appropriate steroid strength for each condition, body area, patient age, and treatment duration. Betnovat sits in the upper range of commonly used topical steroids, making it suitable for moderate-to-severe inflammatory skin conditions that have not responded adequately to milder preparations.
The mechanism of action of betamethasone valerate is characteristic of all glucocorticosteroids. After penetrating the stratum corneum (the outermost layer of the skin), the drug enters epidermal and dermal cells, where it binds to intracellular glucocorticoid receptors in the cytoplasm. The resulting activated receptor-steroid complex translocates to the cell nucleus and interacts with specific DNA sequences called glucocorticoid response elements (GREs). This interaction modulates gene transcription in two key ways: it upregulates the synthesis of anti-inflammatory proteins such as lipocortin-1 (annexin A1), which inhibits the enzyme phospholipase A2, thereby reducing the production of arachidonic acid and its downstream inflammatory mediators (prostaglandins, thromboxanes, and leukotrienes); and it downregulates the expression of pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and various chemokines that recruit immune cells to sites of inflammation.
The clinical effects of betamethasone valerate are threefold: anti-inflammatory (reducing redness, swelling, heat, and tissue damage at sites of inflammation), antipruritic (relieving itching by suppressing the release of histamine and other itch mediators from mast cells), and vasoconstrictive (constricting dilated blood vessels in the dermis, which reduces redness and edema). These combined effects make Betnovat highly effective for a broad spectrum of inflammatory skin conditions. The valerate ester enhances the drug’s lipophilicity, improving its penetration through the skin barrier and increasing its local concentration at the site of action.
Indications and Formulations
Betnovat is indicated for the treatment of a wide range of corticosteroid-responsive inflammatory skin conditions, including but not limited to psoriasis, atopic dermatitis (eczema), contact dermatitis, seborrheic dermatitis, nummular eczema, and other inflammatory dermatoses. The choice of formulation depends on the characteristics of the skin condition, the body area to be treated, and patient preference:
- Betnovat Ointment (0.1%): Formulated with a greasy base of liquid paraffin and white petrolatum. Best suited for dry, thickened, scaly, or lichenified skin lesions. The ointment base provides an occlusive effect that enhances drug penetration and provides additional moisturization. It is the preferred formulation for chronic plaque psoriasis and hyperkeratotic eczema.
- Betnovat Cream (0.1%): A water-based formulation that is lighter and non-greasy. Best suited for moist, weeping, or acutely inflamed skin conditions. The cream is often preferred for application to intertriginous areas (skin folds) and for use during the day when a non-greasy preparation is desired. It spreads easily and is cosmetically more acceptable than the ointment for many patients.
- Betnovat Cutaneous Emulsion (1 mg/ml): A fluid preparation designed for application to large body surface areas and hairy skin. The emulsion is easier to spread over extensive areas than creams or ointments and can be used on the trunk, limbs, and hairy regions of the body.
- Betnovat Cutaneous Solution (1 mg/ml): An alcohol-based clear solution primarily designed for application to the scalp. It is also used to treat inflammation of the external ear canal. The solution is applied via a dropper bottle and is rapidly absorbed without leaving a greasy residue on the hair.
The British Association of Dermatologists (BAD), the National Institute for Health and Care Excellence (NICE), and the European Academy of Dermatology and Venereology (EADV) all support the use of potent topical corticosteroids like betamethasone valerate as a cornerstone of treatment for moderate-to-severe inflammatory skin conditions, particularly when milder corticosteroids have proven insufficient. International guidelines consistently emphasize that treatment should be for the shortest duration necessary, that emollients should be used as adjunctive therapy, and that patients should be educated about the fingertip unit (FTU) system to ensure accurate dosing.
Mechanism of Action in Detail
Beyond the genomic effects described above, betamethasone valerate also exerts rapid non-genomic effects that contribute to its clinical efficacy. These include direct stabilization of cell membranes and lysosomal membranes, which prevents the release of destructive enzymes from lysosomes at inflammatory sites. Betamethasone also inhibits the migration and accumulation of inflammatory cells (neutrophils, monocytes, and lymphocytes) at the site of inflammation by downregulating adhesion molecules on the endothelial surface of blood vessels. Additionally, it suppresses the production of vascular endothelial growth factor (VEGF), contributing to its vasoconstrictive properties. The overall result is a potent suppression of both the early (vascular and exudative) and late (proliferative and fibrotic) phases of the inflammatory response.
Systemic absorption of betamethasone valerate through intact skin is generally low, but it can be significantly increased by several factors: application to thin-skinned areas (face, eyelids, genital region), application over large body surface areas, use of occlusive dressings, application to damaged or inflamed skin (where the skin barrier is compromised), and prolonged treatment duration. In children, systemic absorption is proportionally greater due to their higher body surface area-to-weight ratio. These factors are important considerations in clinical practice and underpin many of the precautions and warnings associated with topical corticosteroid use.
What Should You Know Before Using Betnovat?
Contraindications
Betnovat must not be used in the following situations, as use in these circumstances could worsen the underlying condition or cause significant harm:
- Hypersensitivity: Known allergy to betamethasone, other corticosteroids, or any of the excipients (inactive ingredients) in the specific Betnovat formulation.
- Infected skin: Do not apply Betnovat to skin that is infected by bacteria, fungi, or viruses unless the infection is being treated concurrently with an appropriate antimicrobial agent. Corticosteroids suppress local immune responses and can allow infections to spread or worsen.
- Acne vulgaris: Topical corticosteroids can exacerbate acne and should not be used as acne treatment.
- Rosacea: A chronic facial skin condition characterized by redness, visible blood vessels, papules, and pustules. Topical corticosteroids worsen rosacea and are strictly contraindicated.
- Perioral dermatitis: A papulopustular eruption around the mouth that is worsened and often caused by topical corticosteroid use.
- Non-inflamed pruritus: Itchy skin that is not accompanied by inflammation should not be treated with corticosteroids, as these medications only address the inflammatory component of pruritus.
- Anogenital region: The skin around the anus and genitals is extremely thin and highly susceptible to corticosteroid side effects.
- Children under 1 year: Betnovat is contraindicated in infants due to the high risk of systemic absorption and adrenal suppression.
- Perforated eardrum (solution only): The Betnovat cutaneous solution must not be instilled into the ear canal if the tympanic membrane is perforated, as the alcohol-based solution could damage the middle ear structures.
Warnings and Precautions
Betnovat cream, ointment, and cutaneous emulsion contain paraffin, which is flammable. Fabrics (clothing, bedding, bandages) that have come into contact with the product can ignite more easily. Do not smoke or go near open flames while using these products. Washing fabric may reduce build-up but cannot remove it entirely. The cutaneous solution also contains isopropyl alcohol and is flammable – do not smoke or use near open flame immediately after application.
Local hypersensitivity reactions such as skin redness, rash, itching, hives, burning sensation, and contact eczema may occur. If any skin reaction develops, treatment must be stopped immediately and your doctor consulted. Inform your doctor if you have previously had a hypersensitivity reaction to any corticosteroid preparation.
Duration of treatment: Use Betnovat only for as long as your doctor recommends. If your condition does not improve after 4 weeks of treatment, consult your doctor for reassessment. Prolonged continuous use without medical supervision increases the risk of local and systemic side effects.
Sensitive skin areas: Be particularly cautious when applying Betnovat to the eyelids, and take care to avoid getting the product in the eyes. Long-term application of Betnovat to the face can lead to skin thinning (atrophy), visible blood vessels (telangiectasia), and perioral dermatitis. Sensitive skin areas such as the face, underarms (axillae), groin, and the area around the eyes should only be treated for very short periods.
Leg ulcers: If you have dermatitis (skin inflammation) around a venous leg ulcer, using a topical corticosteroid can increase the risk of allergic contact dermatitis and secondary infection around the wound.
Psoriasis: If you have psoriasis, your doctor will want to see you more frequently during Betnovat treatment, as there is a risk of tolerance development (diminishing effectiveness) and rebound flare upon discontinuation. In rare cases, treatment of psoriasis with potent topical corticosteroids can trigger the development of pustular psoriasis, a more severe and potentially dangerous form of the disease.
Occlusive dressings: Avoid using occlusive dressings over infected eczema. Use occlusive dressings (including a child’s nappy or diaper) only under medical direction. Ensure the skin is thoroughly cleaned before applying a new dressing to prevent secondary infection. Occlusive dressings significantly increase corticosteroid absorption and the risk of systemic effects.
Prolonged use of high-dose Betnovat, especially over large body areas or under occlusive dressings, can lead to sufficient systemic absorption to produce Cushing’s syndrome. Symptoms include weight gain with altered fat distribution (trunk, neck, face – “moon face”), thin and fragile skin, increased body hair, decreased bone density (osteoporosis), and elevated blood pressure. In children and adolescents, growth retardation may occur. If any of these symptoms are observed, contact your doctor for a plan to gradually discontinue treatment. Abrupt cessation can result in glucocorticoid insufficiency (adrenal crisis).
Visual disturbances: Contact your doctor if you experience blurred vision or other visual disturbances during treatment, as these may indicate rare but serious complications such as cataract or glaucoma.
Masking infections: Corticosteroids can mask the signs and symptoms of a developing skin infection, or activate or worsen existing infections. Contact your doctor promptly if signs of infection (increasing redness, warmth, swelling, pus, or pain) develop during treatment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, do not use Betnovat without first consulting your doctor. The safety of topical betamethasone valerate during pregnancy has not been established in adequate human studies. Animal studies with corticosteroids have demonstrated teratogenic effects, including cleft palate and intrauterine growth restriction. While topical corticosteroids have not been conclusively shown to cause birth defects in humans, the possibility cannot be excluded, particularly with prolonged use over large areas. If Betnovat is prescribed during pregnancy, it should be applied to the smallest area possible for the shortest time necessary.
If you are breastfeeding, consult your doctor before using Betnovat. It is not known whether betamethasone valerate passes into breast milk after topical application. If Betnovat is used during breastfeeding, it must not be applied to the breasts, to prevent the infant from inadvertently ingesting the medication.
Driving and Operating Machinery
Betnovat has no known effect on the ability to drive vehicles or operate machinery.
How Does Betnovat Interact with Other Drugs?
Although topical corticosteroids are primarily applied locally and systemic absorption is generally low, drug interactions can occur when sufficient amounts of the active ingredient enter the systemic circulation. This is more likely with prolonged use, application over large body surface areas, use of occlusive dressings, or application to damaged skin. The most clinically significant interactions involve drugs that inhibit the cytochrome P450 3A4 (CYP3A4) enzyme, which is the primary enzyme responsible for the hepatic metabolism of betamethasone. Inhibition of CYP3A4 slows the breakdown of any systemically absorbed betamethasone, increasing its circulating levels and the risk of systemic corticosteroid side effects.
Major Interactions
The following medications are specifically cited in the product information as interacting with Betnovat. Co-administration with these drugs increases the risk of systemic corticosteroid effects, including adrenal suppression and Cushing’s syndrome:
| Drug | Drug Class | Mechanism | Clinical Significance |
|---|---|---|---|
| Ritonavir | HIV protease inhibitor / Pharmacokinetic booster | Potent CYP3A4 inhibitor – greatly reduces metabolism of betamethasone | High – increased risk of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression |
| Itraconazole | Azole antifungal | Strong CYP3A4 inhibitor – reduces hepatic clearance of betamethasone | High – increased systemic exposure to betamethasone |
Other Potential Interactions
While not specifically listed in the Betnovat product information, other strong CYP3A4 inhibitors may also increase systemic betamethasone levels through the same pharmacokinetic mechanism. Healthcare providers should be aware of the potential for interaction with these drugs, particularly when Betnovat is being used over large body areas or under occlusion:
| Drug | Drug Class | CYP3A4 Inhibition Strength |
|---|---|---|
| Ketoconazole | Azole antifungal | Strong |
| Cobicistat | Pharmacokinetic enhancer (HIV) | Strong |
| Clarithromycin | Macrolide antibiotic | Strong |
| Erythromycin | Macrolide antibiotic | Moderate |
| Voriconazole | Azole antifungal | Strong |
Always inform your doctor or pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. This is especially important if you are using Betnovat on large body areas, under occlusive dressings, for prolonged periods, or on damaged skin, as systemic absorption is increased in these situations.
What Is the Correct Dosage of Betnovat?
Always use Betnovat exactly as your doctor has instructed. If you are unsure, consult your doctor or pharmacist. The fundamental principle of topical corticosteroid therapy is to use the minimum amount necessary to cover the affected area, for the shortest duration that effectively controls symptoms. Overuse leads to increased risk of local side effects (skin thinning, stretch marks) and systemic effects (adrenal suppression), while underuse results in inadequate symptom control. The fingertip unit (FTU) system is widely recommended as a practical guide: one FTU (the amount of cream squeezed from a standard tube along the tip of an adult’s index finger from the tip to the first crease) covers approximately two flat adult hands worth of skin area.
Adults
Standard Adult Dosage
Apply a thin layer of Betnovat to the affected area once or twice daily, as directed by your doctor. Gently rub the preparation into the skin until it has been absorbed. Wash your hands thoroughly after application, unless the hands are the area being treated. Most patients respond well to once-daily application, and the British National Formulary (BNF) advises that once-daily application is sufficient for potent topical corticosteroids in most cases.
Emollients: If you are also using an emollient (moisturizer), apply Betnovat first and wait at least 15–30 minutes before applying the emollient, to ensure that the corticosteroid is adequately absorbed. Some guidelines suggest the opposite order (emollient first), so follow your doctor’s specific instructions.
Maximum duration: Betnovat should not be used every day for longer than 4 consecutive weeks. For longer-term management of chronic conditions, your doctor may recommend an intermittent regimen (for example, application on 2–3 days per week with emollients on the other days) or may rotate Betnovat with a milder corticosteroid.
Children
Betnovat is not generally suitable for routine use in children without specific medical direction. Children are more susceptible to systemic absorption due to their higher body surface area-to-weight ratio. Use the smallest effective amount for the shortest possible time. Betnovat is contraindicated in children under 1 year.
Children (1 year and older, under medical supervision only)
Use the smallest possible amount to cover only the affected area, applied as directed by the prescribing physician. Treatment duration should be limited to a few days to a maximum of 2 weeks unless otherwise instructed by a specialist. Avoid use under occlusive dressings (including nappies/diapers), as this dramatically increases absorption.
Elderly Patients and Patients with Liver or Kidney Impairment
Special Populations
Elderly patients and those with impaired liver or kidney function should use the smallest possible amount for the shortest possible duration. The skin of elderly patients is generally thinner and more fragile, increasing susceptibility to corticosteroid side effects. Patients with hepatic impairment may have reduced capacity to metabolize systemically absorbed betamethasone.
Scalp Application (Cutaneous Solution)
If you wash your hair, allow it to dry completely before applying Betnovat solution. Unscrew the cap and place the nozzle of the bottle against the scalp. Squeeze the bottle gently to dispense a thin, even layer of solution over the affected area. You may massage the solution into the scalp but this is not essential. The scalp will feel cool until the solution dries, as the formulation contains isopropyl alcohol. The solution is flammable – do not smoke, use near open flames, or apply near heat sources immediately after application.
Ear Canal Application (Cutaneous Solution)
For treatment of inflammation of the external ear canal (otitis externa), the affected area should first be cleaned thoroughly. Instill 2–3 drops into the ear canal 2–3 times daily. For chronic or persistent ear conditions, treatment should be carried out under the supervision of an ear, nose, and throat (ENT) specialist. Do not use if the eardrum is perforated.
Missed Dose
If you forget to apply Betnovat, apply it as soon as you remember and then continue with your usual schedule. Do not apply extra to make up for a missed dose. If it is almost time for your next application, simply skip the missed dose and continue as normal.
Overdose
Acute overdose from topical application is unlikely. However, prolonged overuse or misapplication of Betnovat can lead to chronic overdose, manifested as local skin changes (thinning, stretch marks, visible blood vessels) and/or systemic corticosteroid effects (adrenal suppression, Cushing’s syndrome). If you suspect chronic overdose or have been using Betnovat incorrectly for an extended period, contact your doctor for assessment and guidance. Do not stop treatment abruptly – your doctor will advise on how to taper the dose safely.
Stopping Betnovat
If you have been using Betnovat regularly, especially over large areas or for prolonged periods, do not stop abruptly. Talk to your doctor before discontinuing treatment. Your doctor will typically recommend gradually reducing the frequency of application – for example, from daily to every other day, then to twice a week, then once a week – before stopping entirely. Abrupt discontinuation after prolonged use can cause a rebound flare of the underlying condition, characterized by intense redness, burning, and stinging, and in severe cases may precipitate adrenal insufficiency.
What Are the Side Effects of Betnovat?
Like all medicines, Betnovat can cause side effects, although not everyone experiences them. The risk of side effects increases with prolonged use, application over large body areas, use of occlusive dressings, and application to sensitive or damaged skin. If your skin symptoms worsen or your skin becomes swollen during treatment, you may be experiencing an allergic reaction to the medication, a secondary infection, or may need a different treatment approach. In such cases, stop using Betnovat and contact your doctor as soon as possible.
Common
May affect up to 1 in 10 users
- Itching at the application site
- Local burning sensation or pain
Uncommon
May affect up to 1 in 100 users
- Skin thinning (atrophy) that may lead to stretch marks (striae)
- Rash on the face
Rare
May affect up to 1 in 1,000 users
- Changes in skin pigmentation (lightening or darkening)
- Increased body hair growth (hypertrichosis)
Very Rare
May affect up to 1 in 10,000 users
- Local hypersensitivity reactions (redness, rash, hives, burning)
- Adrenal suppression (reduced adrenal gland function)
- Weight gain, obesity, Cushingoid features (moon face, central fat accumulation)
- Skin wrinkling, dry skin
- Visible blood vessels under the skin (telangiectasia)
- Hair loss, impaired hair growth, hair damage
- Contact eczema or skin infection at the application site
- Worsening of existing symptoms
- Pustular psoriasis (very rare complication in psoriasis patients)
- Delayed weight gain or slowed growth in children
- Decreased cortisol levels in the blood
- Elevated blood sugar or urine sugar levels
- Opportunistic infections (infections occurring due to suppressed immune function)
- Elevated blood pressure
- Cataract (clouding of the lens of the eye)
- Glaucoma (increased pressure within the eye)
- Osteoporosis (weakening of the bones)
Not Known
Frequency cannot be estimated from available data
- Blurred vision
The majority of the very rare systemic side effects listed above are associated with prolonged use of potent topical corticosteroids over large body surface areas, particularly under occlusive dressings. When Betnovat is used as directed (thin application to limited areas for short periods), the risk of these systemic effects is very low. Nevertheless, patients should be vigilant for any new symptoms during treatment and report them to their healthcare provider promptly.
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Betnovat?
Proper storage of Betnovat is essential to maintain the drug’s stability, efficacy, and safety throughout its shelf life. The following storage guidelines apply to all Betnovat formulations:
- Temperature: Store at or below 25°C (77°F). Do not freeze. Avoid exposing the product to excessive heat or direct sunlight, as this may degrade the active ingredient or alter the consistency of the formulation.
- Child safety: Keep out of the sight and reach of children. Topical corticosteroids can cause significant harm if accidentally ingested by children.
- Expiry date: Do not use Betnovat after the expiry date stated on the packaging (after “EXP”). The expiry date refers to the last day of the indicated month.
- After opening: Once opened, use within the period specified on the packaging. Close the tube or bottle securely after each use to prevent contamination.
- Flammability: The cutaneous solution contains isopropyl alcohol and is flammable. Store away from heat, open flame, and ignition sources. The cream, ointment, and emulsion contain paraffin (also flammable) and should similarly be stored with care.
- Disposal: Do not dispose of Betnovat in wastewater or household waste. Return unused or expired medicine to your pharmacy for proper disposal. This helps protect the environment.
What Does Betnovat Contain?
The active substance in Betnovat is betamethasone, present as betamethasone valerate. The concentration is standardized across all formulations: 1 mg of betamethasone (as betamethasone valerate) per gram of ointment or cream, or per milliliter of emulsion or solution. This corresponds to a strength of 0.1%. The excipients (inactive ingredients) differ between formulations and serve specific pharmaceutical functions including emulsification, preservation, viscosity adjustment, and skin penetration enhancement.
| Formulation | Active Ingredient | Key Excipients | Packaging |
|---|---|---|---|
| Ointment | Betamethasone valerate 1 mg/g | Liquid paraffin, white petrolatum (vaseline) | Aluminium tube, 30 g or 100 g |
| Cream | Betamethasone valerate 1 mg/g | Chlorocresol (preservative), macrogol cetostearyl ether, cetostearyl alcohol, white petrolatum, liquid paraffin, sodium dihydrogen phosphate, phosphoric acid, sodium hydroxide, purified water | Aluminium tube, 30 g or 100 g |
| Cutaneous emulsion | Betamethasone valerate 1 mg/ml | Methyl parahydroxybenzoate (preservative, E218), xanthan gum, cetostearyl alcohol, liquid paraffin, isopropyl alcohol, glycerol, macrogol cetostearyl ether, sodium citrate, citric acid monohydrate, purified water | Plastic bottle, 100 ml |
| Cutaneous solution | Betamethasone valerate 1 mg/ml | Carbomer, isopropyl alcohol, sodium hydroxide, water | Plastic bottle, 30 ml or 100 ml |
Appearance: Betnovat ointment is white to semi-translucent. The cream is white. The cutaneous emulsion is white. The cutaneous solution is a clear, transparent liquid with an isopropyl alcohol odor.
Some of the excipients in Betnovat formulations may themselves cause allergic reactions in sensitive individuals. Chlorocresol (in the cream) and methyl parahydroxybenzoate (in the emulsion) are preservatives known to occasionally cause contact sensitization. Cetostearyl alcohol (in the cream and emulsion) can cause local skin reactions in some patients. If you know you are allergic to any of these substances, inform your doctor so an alternative formulation can be selected.
Marketing authorization holder: GlaxoSmithKline (GSK). Betnovat is manufactured at multiple sites across Europe, including facilities in Poland, Ireland, and Germany.
Frequently Asked Questions About Betnovat
Betnovat contains betamethasone valerate, a potent (Group III) topical corticosteroid. It is used to treat inflammatory skin conditions including psoriasis, eczema (atopic dermatitis), contact dermatitis, and other corticosteroid-responsive dermatoses. The ointment is best for dry, scaly skin; the cream suits moist or weeping conditions; the emulsion covers large or hairy areas; and the solution is designed for the scalp and ear canal inflammation.
Betnovat (betamethasone valerate 0.1%) is classified as a potent (Group III) topical corticosteroid in the European four-tier classification system. It is stronger than mild steroids like hydrocortisone 1% and moderate steroids like clobetasone butyrate 0.05%, but less potent than very potent (Group IV) steroids like clobetasol propionate 0.05%. This makes it suitable for moderate-to-severe inflammatory skin conditions when milder steroids have been insufficient.
Betnovat should generally not be used on the face without specific medical instruction. Facial skin is thinner and more susceptible to corticosteroid side effects including skin thinning (atrophy), visible blood vessels (telangiectasia), stretch marks, and perioral dermatitis. If your doctor prescribes Betnovat for facial use, it should only be applied for very short periods under close medical monitoring. Milder corticosteroids such as hydrocortisone are usually preferred for the face.
Betnovat should not be used daily for more than 4 weeks at a time without medical supervision. For the face and other sensitive areas, shorter treatment periods are recommended (typically 5–7 days). Long-term continuous use increases the risk of skin thinning, stretch marks, and systemic absorption. If your condition requires ongoing treatment, your doctor may recommend intermittent use (e.g., a few days per week) or alternating with emollients and milder corticosteroids.
Yes. Betnovat cream, ointment, and cutaneous emulsion contain paraffin, which is flammable. Fabrics such as clothing, bedding, and bandages that come into contact with the product can ignite more easily. You should avoid smoking, open flames, and other ignition sources during treatment. Washing fabrics may reduce product build-up but cannot remove it entirely. The cutaneous solution also contains isopropyl alcohol, making it flammable as well.
Betnovat should not be used during pregnancy unless specifically advised by your doctor, as the safety of topical betamethasone during pregnancy has not been fully established. Animal studies have shown potential risks to the developing fetus with corticosteroids. If you are breastfeeding, consult your doctor before using Betnovat, and do not apply it to the breasts to prevent accidental ingestion by the infant.
References
All information in this article is based on international medical guidelines, peer-reviewed research, and official product information. No commercial funding was involved in the production of this content.
- 1 European Medicines Agency (EMA). Betamethasone Valerate – Summary of Product Characteristics. Accessed February 2026.
- 2 British National Formulary (BNF). Betamethasone Valerate Monograph. National Institute for Health and Care Excellence (NICE), 2024–2025.
- 3 British Association of Dermatologists (BAD). Guidelines for the Management of Atopic Eczema. British Journal of Dermatology, 2024.
- 4 National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary: Corticosteroids – Topical (Skin), Nose, and Eyes. Updated 2024.
- 5 World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO, 2023.
- 6 Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology. 2006;54(1):1-15. doi:10.1016/j.jaad.2005.01.010
- 7 Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian Journal of Dermatology. 2012;57(4):251-259. doi:10.4103/0019-5154.97655
- 8 Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023
- 9 U.S. Food and Drug Administration (FDA). Betamethasone Valerate – Prescribing Information. Accessed February 2026.
- 10 Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update: Emollients and Risk of Fire. November 2018.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in clinical pharmacology, dermatology, and evidence-based medicine. All content follows the GRADE evidence framework and adheres to international clinical guidelines from WHO, EMA, FDA, BNF, NICE, and the BAD.
Evidence Level 1A based on systematic reviews, meta-analyses, and international clinical guidelines. No commercial funding. Independent editorial process.
All drug monographs are reviewed by at least two qualified medical professionals. Content is updated regularly to reflect the latest evidence and regulatory changes.
For questions about our editorial standards, visit our Editorial Standards page. To contact our medical team, visit our Contact page.